4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday

Key Points

• 4D Molecular Therapeutics is set to announce its Q2 2025 earnings on August 14th, with anticipated earnings of ($0.69) per share and revenue of $0.52 million.
• Last reported earnings showed a loss of ($0.86) per share, missing analyst expectations, while analysts forecast $-3 EPS for both the current and next fiscal years.
• Analyst ratings are mixed, with seven buy ratings and a consensus target price of $29.56, despite recent downward adjustments from firms like Goldman Sachs and Barclays.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect 4D Molecular Therapeutics to post earnings of ($0.69) per share and revenue of $0.52 million for the quarter.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. On average, analysts expect 4D Molecular Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

4D Molecular Therapeutics Trading Down 2.6%

Shares of NASDAQ:FDMT traded down $0.15 during midday trading on Friday, hitting $5.63. The stock had a trading volume of 552,736 shares, compared to its average volume of 2,244,897. The company has a market capitalization of $260.84 million, a PE ratio of -1.77 and a beta of 2.83. The stock has a 50 day moving average price of $4.42 and a two-hundred day moving average price of $4.08. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $17.41.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of FDMT. Millennium Management LLC raised its position in shares of 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock valued at $5,278,000 after buying an additional 213,264 shares during the last quarter. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics during the first quarter worth approximately $46,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics during the first quarter worth approximately $39,000. Institutional investors and hedge funds own 99.27% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on FDMT. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, August 1st. Barclays decreased their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. The Goldman Sachs Group decreased their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Tuesday, July 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.56.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.